Literature DB >> 26652969

Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety.

Hao Zhang1, Min-Hang Xin1, Xiao-Xiao Xie1, Shuai Mao1, Sai-Jie Zuo1, She-Min Lu2, San-Qi Zhang3.   

Abstract

In present study, a series of N-(2-methoxy-5-(3-substituted quinazolin-4(3H)-one-6-yl)-pyridin-3-yl)phenylsulfonamide were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against HCT116 and MCF-7 cancer cell lines. The SAR of title compounds was discussed. The compounds (S)-C5 and (S)-C8 displayed potent inhibitory activity against PI3Ks and mTOR, especially against PI3Kα. In addition, compound (S)-C5 can efficaciously inhibit tumor growth in a mice S-180 model. These findings suggest that our designed compounds can serve as potent PI3K inhibitors and effective anticancer agents.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Antitumor activity; PI3K inhibitor; Quinazolin-4(3H)-ones; Synthesis

Mesh:

Substances:

Year:  2015        PMID: 26652969     DOI: 10.1016/j.bmc.2015.11.027

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

1.  Discovery of 3-Quinazolin-4(3H)-on-3-yl-2,N-dimethylpropanamides as Orally Active and Selective PI3Kα Inhibitors.

Authors:  Jiaqiang Dong; Jingjie Huang; Ji Zhou; Ye Tan; Jing Jin; Xi Tan; Bei Wang; Tao Yu; Chengde Wu; Shuhui Chen; Tie-Lin Wang
Journal:  ACS Med Chem Lett       Date:  2020-06-10       Impact factor: 4.345

2.  Synthesis and biological evaluation of 12-N-p-chlorobenzyl sophoridinol derivatives as a novel family of anticancer agents.

Authors:  Chongwen Bi; Cheng Ye; Yinghong Li; Wuli Zhao; Rongguang Shao; Danqing Song
Journal:  Acta Pharm Sin B       Date:  2016-04-14       Impact factor: 11.413

Review 3.  Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.

Authors:  Yu Liu; Wen-Zhu Wan; Yan Li; Guan-Lian Zhou; Xin-Guang Liu
Journal:  Oncotarget       Date:  2017-01-24

4.  Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.

Authors:  Minhang Xin; Weiming Duan; Yifan Feng; Yuan-Yuan Hei; Hao Zhang; Ying Shen; Hong-Yi Zhao; Shuai Mao; San-Qi Zhang
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.